Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma

NCT01222715 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01222715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01222715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Bevacizumab (Avastin) and Temsirolimus (Torisel) in Combination With Intravenous Vinorelbine and Cyclophosphamide in Patients With Recurrent/Refractory Rhabdomyosarcoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
June 30, 2015
Enrollment
87 (actual)
Sites
184

Conditions

As the registry lists them; a condition with its own page is linked.

adult rhabdomyosarcoma, childhood alveolar rhabdomyosarcoma, childhood pleomorphic rhabdomyosarcoma, childhood rhabdomyosarcoma with mixed embryonal and alveolar features, previously treated childhood rhabdomyosarcoma, recurrent adult soft tissue sarcoma, recurrent childhood rhabdomyosarcoma